This study aimed to investigate the value of magnetic resonance spectroscopy (MRS) imaging in assessing nasopharyngeal carcinoma radiotherapy during the early delayed reaction period. Eighty cases of nasopharyngeal cancer treated with radiotherapy within the same period underwent MRS imaging before or after radiotherapy. Of the 80 cases, 47 underwent MRS imaging on the 3rd, 4th, 6th, and 12th months after radiotherapy. The trends of the primary metabolite concentration at different time points were monitored and compared with the corresponding data after radiotherapy. Repeated measures analysis of variance was performed. At the end of radiotherapy, the N-acetyl aspartate (NAA)/creatine (Cr), choline (Cho)/Cr, and NAA/Cho ratios were reduced to the lowest levels after 3 months. However, increasing trends were observed from the 4th to the 12th month. On the 12th month, stable levels were reached with statistically significant differences (F = 316.02, 53.84, 286.68; P < 0.01). MRS reflected the radiation injury-repair process in the brain of a nasopharyngeal cancer patient during early delayed reaction. This non-invasive monitoring of changes in brain tissue metabolite concentrations provides valuable information for prognosis.

An adjustable chromaticity layer was successfully applied to a TBADN-based blue organic light-emitting device (BOLED) for improving chromaticity and luminance efficiency. The device was constructed by sandwiching an ultrathin [DPVBi: BCzVB] layer between hole-transport layer and primary emission layer. The optimized device gives the Commission Internationale de I'éclairage (CIE) color coordinates of (0.166, 0.201) at the current density of 20 mA/cm 2 and a maximum luminance efficiency of 8.43 cd/A at the driving voltage of 11 V.